仿真技术在单片机实验室建设中的应用

针对传统实物单片机实验室建设中存在的一些问题,提出采用Proteus仿真软件建立仿真实验室,设计制作一套51系列单片机实验系统。该系统基本包含实物实验箱中的所有模块,与硬件实物箱比较,既方便进行验证性的实验,又方便进行拓展性的实验。实验理念与以往有很大的差异,学生在学习实验过程中能够更大胆地去创新。单片机仿真实验室是一个完全开放型的实验室,它的建立既有利于教师开展实践教学,更有利于学生实践及工程能力的培养。     

Scutellarein Inhibits LPS-Induced Inflammation through NF-κB/MAPKs Signaling Pathway in RAW264.7 Cells

Inflammation is a severe topic in the immune system and play a role as pro-inflammatory mediators. In response to such inflammatory substances, immune cells release cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Lipopolysaccharide (LPS) is known as an endotoxin in the outer membrane of Gram-negative bacteria, and it catalyzes inflammation by stimulating the secretion of inflammatory-mediated cytokines such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) by stimulated immune cells. Among the pathways involved in inflammation, nuclear factor kappa (NF-кB) and mitogen-activated protein kinases (MAPKs) are important. NF-kB is a diploid composed of p65 and IkBα and stimulates the pro- gene. MAPKs is a family consisting of the extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and p38, JNK and p38 play a role as proinflammatory mediators. Thus, we aim to determine the scutellarein (SCU) effect on LPS stimulated RAW264.7 cells. Furthermore, since scutellarein has been shown to inhibit the SARS coronavirus helicase and has been used in Chinese medicine to treat inflammatory disorders like COVID-19, it would be required to examine scutellarein’s anti-inflammatory mechanism. We identified inflammation-inducing substances using western blot with RAW264.7 cells and SCU. And we discovered that was reduced by treatment with SCU in p-p65 and p-IκBα. Also, we found that p-JNK and p-ERK were also decreased but there was no effect in p-p38. In addition, we have confirmed that the iNOS was also decreased after treatment but there is no change in the expression of COX-2. Therefore, this study shows that SCU can be used as a compound to treat inflammation.     

DICOM图像显示与传输的研究与实现

本文在研究DICOM 3．0协议的基础上,阐述了DICOM图像的存储结构,深入研究了DICOM通信协议,设计并实现了DICOM图像显示与传输系统。     

欧盟钢铁减排路线图及其启示

 欧盟委员会于2019年底发布《欧洲绿色协议》，提出将在2050年率先实现碳中和。欧盟为此提出了七大绿色行动计划和四大支撑保障措施，并特别针对钢铁行业提出了明确的欧盟钢铁减排路线图。论述了欧盟绿色新政的背景和意义，分析了欧盟各个行业实现碳中和的具体要求，比较了钢铁减排路线图中的具体技术，讨论了欧盟实施减排的政策措施，探讨了其对我国未来的钢铁行业绿色可持续发展的启示。     

川西老区中浅层新型泡排药剂研发与应用

川西老区中浅层气井已总体处于低压低产阶段，井口压力低于1 MPa占比76.13%，产量低于0.2$\times$10$^4$m$^3$/d占比57.14%，80.62%的气井已介入泡排工艺，但泡排工艺效果逐渐变差。针对高含凝析油气井泡排效果差、低压低产气井泡排低效及积液与乳化并存致气井治理难度大等问题，研发了3种新型SCU系列泡排剂。通过建立CHSB—SDS—PFBS三元表面活性剂体系，研发了高抗凝析油泡排药剂SCU—2，可将气液表面张力降低至26.73 mN/m，抗凝析油含量达50%；优选反应体系及催化剂，研发了自生能量型泡排药剂SCU—3，可在井筒发生化学反应生成N$_2$，并释放热量，提高低压低产井泡沫举升效率；优选复合酸与抗油性表面活性剂复配，研发了净化与排液一体化药剂SCU—6，同等浓度下降黏能力优于常规净化剂，起泡能力优于常规泡排剂。SCU系列药剂应用138口井，有效率89.73%，增产天然气774$\times$10$^4$m$^3$。新药剂拓展了泡排工艺技术的应用范围，具有良好推广应用前景。